Sustained-Release Pharmaceutical Compositions Comprising Antipsychotic Drug
Summary
The EPO granted patent EP3833333A1 to Taiwan Liposome Company, Ltd. and TLC Biopharmaceuticals, Inc. for sustained-release antipsychotic drug compositions using liposomal delivery technology. The patent covers formulations of atypical antipsychotics including quetiapine and clozapine for extended drug release over 24 hours to two weeks.
What changed
The EPO published patent EP3833333A1 granting Taiwan Liposome Company and TLC Biopharmaceuticals exclusive rights to sustained-release antipsychotic drug compositions. The compositions utilize liposomal delivery systems (A61K9/127) with antipsychotic agents including quetiapine and clozapine, designed for extended release over 24 hours to two weeks. The patent designates all major European contracting states including Germany, France, UK, Italy, Spain, and the Netherlands.
Pharmaceutical companies developing liposomal antipsychotic formulations should review this patent for potential licensing needs or design-around strategies. Competitors in the extended-release CNS drug space should assess freedom-to-operate before entering the European market. Patent holders seeking similar protection may need to demonstrate differentiation from this established liposomal approach.
What to do next
- Monitor patent database for related continuation applications
- Review Freedom to Operate for antipsychotic drug delivery products
- Update IP portfolio tracking for pharmaceutical companies
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND USES THEREOF
Publication EP3833333A1 Kind: A1 Apr 01, 2026
Applicants
Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.
Inventors
HONG, Keelung, FANG, Jonathan, KAO, Hao-Wen, LIN, Yi-Yu, GWATHNEY, Walter
IPC Classifications
A61K 9/127 20060101AFI20220330BHEP A61K 47/24 20060101ALI20220330BHEP A61K 47/28 20060101ALI20220330BHEP A61P 25/18 20060101ALI20220330BHEP A61K 31/496 20060101ALI20220330BHEP A61K 31/551 20060101ALI20220330BHEP A61K 47/18 20170101ALI20220330BHEP A61K 31/519 20060101ALI20220330BHEP A61K 31/554 20060101ALI20220330BHEP A61K 31/5513 20060101ALI20220330BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.